Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. 51st Annual Meeting and Exposition of the American-Society-of-Hematology Pollyea, D. A., Smith, S., Fowler, N., Boyd, T. E., Smith, A. M., Sirisawad, M., Honigberg, L. A., Hamdy, A., Advani, R. AMER SOC HEMATOLOGY. 2009: 1430–30
View details for Web of Science ID 000272725804377